# Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Source: https://onco.cc/trials/nct05280470/  
OnCo record `nct05280470` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ifinatamab deruxtecan in small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.

## Summary

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a phase 2 interventional study registered as NCT05280470 by Daiichi Sankyo, with 187 participants enrolled, started 2022-03-09 and due to reach its primary completion in 2025-03-03. Interventions recorded: Ifinatamab Deruxtecan (I-DXd). Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05280470
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), in Subjects With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)
- Sponsor: Daiichi Sankyo
- Enrolled: 187

## Sources

- ClinicalTrials.gov NCT05280470: https://clinicaltrials.gov/study/NCT05280470

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct05280470.json